PSILOCYBIN AS AN ADJUNCTIVE TREATMENT FOR DEPRESSION AND PSYCHOLOGICAL DISTRESS IN ONCOLOGY: CURRENT EVIDENCE AND CLINICAL IMPLICATIONS
DOI:
https://doi.org/10.31435/ijitss.1(49).2026.5034Keywords:
Psilocybin, Cancer, Depression, Psychological Distress, Oncology, Palliative Care, Adjunctive TreatmentAbstract
Depression and psychological distress are highly prevalent among patients with cancer and are associated with impaired quality of life, reduced treatment adherence, and poorer clinical outcomes. Standard pharmacological and psychosocial interventions often demonstrate limited efficacy or delayed onset of action in oncological and palliative settings. Psilocybin-assisted therapy has recently emerged as a potential adjunctive approach for the treatment of depression, anxiety, and existential distress in patients with life-threatening cancer.
This narrative review synthesizes current clinical and neurobiological evidence regarding the use of psilocybin as an adjunctive treatment in oncology. Randomized controlled trials, systematic reviews, and case reports indicate that psilocybin administered within a structured psychotherapeutic framework may produce rapid and sustained reductions in depressive symptoms and anxiety, including improvements in existential well-being. Mechanistic findings suggest involvement of serotonergic 5-HT2A receptor activation, large-scale brain network modulation, and enhanced neuroplasticity.
When applied in controlled clinical settings with appropriate screening and psychological support, psilocybin demonstrates a favorable safety profile. Although current evidence is promising, limitations related to sample size and methodological heterogeneity require cautious interpretation. Further well-designed trials are necessary to determine long-term efficacy and optimal integration into comprehensive cancer and palliative care.
References
Vita, G., Compri, B., Matcham, F., Barbui, C., & Ostuzzi, G. (2023). Antidepressants for the treatment of depression in people with cancer. Cochrane Database of Systematic Reviews, 2023(3), CD011006. https://doi.org/10.1002/14651858.CD011006.pub4
Wierzbicka, M., Kopczyk, R., Gerlach, A., & Rymaszewska, J. (2025). Therapeutic and legal aspects of psilocybin in cancer-related depression. Frontiers in Psychiatry, 16, 1591864. https://doi.org/10.3389/fpsyt.2025.1591864
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., et al. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512
Moshfeghinia, R., Mostafavi, S., Kiani, A., et al. (2025). The effects of psilocybin on psychological distress in cancer patients: A systematic review and meta-analysis. BMC Psychology, 13, 393. https://doi.org/10.1186/s40359-025-03935-y
Schuman, H. D. M., Savard, C., Mina, R., Barkova, S., Conradi, H. S. W., Deleemans, J. M., & Carlson, L. E. (2025). Psychedelic-assisted therapies for psychosocial symptoms in cancer: A systematic review and meta-analysis. Current Oncology, 32, 380. https://doi.org/10.3390/curroncol32070380
Patchett-Marble, A., Swift, J. K., McGee, S., et al. (2022). Psilocybin mushrooms for psychological and existential distress in a patient with palliative lung cancer. Canadian Family Physician, 68(11), 823–826. https://doi.org/10.46747/cfp.6811823
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., et al. (2021). Effects of psilocybin-assisted therapy on major depressive disorder. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285
Shao, L. X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021). Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron, 109(16), 2535–2544. https://doi.org/10.1016/j.neuron.2021.06.008
Siegel, J. S., Subramanian, S., Perry, D., Kay, B. P., Gordon, E. M., Laumann, T. O., et al. (2024). Psilocybin desynchronizes the human brain. Nature, 630, 754–761. https://doi.org/10.1038/s41586-024-07624-5
Goodwin, G. M., Croal, M., Feifel, D., Kelly, J. R., Marwood, L., Mistry, S., et al. (2023). Psilocybin for treatment-resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology, 48, 1492–1499. https://doi.org/10.1038/s41386-023-01648-7
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Anna Komarczewska, Michał Kociński, Patryk Iglewski, Michał Pietrasz, Jakub Idziński, Anna Lubomska
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
